Los Angeles, CA (PRWEB) June 21, 2012
The Actos Resource Center, a patient advocacy group, is alerting those patients who have taken the drug Actos for their type II diabetes of a British study released this month which links the medication to macular edema. This is in addition to previous studies associating the drug with bladder cancer.
Anyone who has experienced symptoms of blurred vision, heart problems or bladder cancer after taking Actos is encouraged to visit their doctor and speak with a lawyer about their legal options.
For more than a year, warnings have surfaced over the safety of extended use of Actos. On June 10, 2011, CBS News reported that Germany and France had banned Actos after a study indicated long-term use could increase bladder cancer occurrences by as much as 40%. The FDA followed up on June 15, 2011 by issuing its own alert about the drug.
In April, the Canadian Press reported that Health Canada was issuing a warning after a study there showed a greater than 40% increased risk of bladder cancer from Actos. On May 31st, the British Medical Journal published a study from McGill University in Montreal finding the increased bladder cancer risks from long-term Actos use may actually be as high as 83%.
Now, on June 14, 2012, the Archives of Internal Medicine reported a study from the University of Nottingham which suggests that drugs like Actos can double or triple the risk of macular edema. The disease occurs when fluid leaks into the center of the eye’s macula, causing blurred vision.
Studying more than 100,000 people with Type 2 diabetes, British researchers found that 1.3% of patients taking a drug like Actos after a year developed macular edema, compared to 0.2% of patients not on the medications.
Anyone who has suffered bladder cancer, heart disease or vision problems while taking Actos is urged to speak with a lawyer about their legal options. According to Bloomberg News on March 13, 2012, Takeda Pharmaceuticals could face as many as 10,000 lawsuits in the U.S. from patients suffering serious side effects from their drug.
A federal Judicial Panel has consolidated all Actos lawsuits to a special multi-district federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).
The Actos Resource Center cautions anyone affected that it is important to choose a lawyer with experience in these types of MDL cases. The Actos Resource Center works only with qualified Actos lawyers who are actively involved in this litigation and have handled thousands of cases.
For more information on the a possible actos class action lawsuit, research, warnings, side effects and legal options relating to the drug Actos, or to speak with a lawyer, visit http://www.ActosCancer.com.